Mukuru and WorldRemit Partner to Further Expand Remittance Service into Southern Africa
Mukuru and WorldRemit today announced a deepening of their existing partnership. Having initially launched the alliance in Zimbabwe, the two companies aim to expand their collaboration for cash remittances into Zambia, South Africa, Mozambique, Malawi and Botswana. This is an important next step in furthering the delivery of world-class services and financial inclusion across the African continent.
The partnership expansion is the latest move by both companies to enhance the delivery of financial services to customers by combining their strengths and leveraging their capabilities and resources.
As a result of the company's deepened collaboration, customers will benefit from guaranteed cash at all times, and there will be no cash-out charges to recipients on cash collections. Until now, customers who received payments into mobile wallets in partnership countries like Zambia would ordinarily pay a cash-out fee when withdrawing cash from a mobile wallet. Now, when a WorldRemit customer sends cash to a recipient in Zambia, and that recipient collects their transfer at a Mukuru booth, the recipient will pay no fee at all.
Since the launch of the partnership in June 2020, WorldRemit customers in over 50 countries – including the United Kingdom, United States, Australia, New Zealand, Canada and Europe – have been able to send money to their loved ones in Zimbabwe who are in need of financial resources as the coronavirus pandemic draws out. Beneficiaries can collect their WorldRemit remittance at any of Mukuru’s 150+ orange booths and multiple branches located across Zimbabwe in both rural and peri-urban areas.
The cash pick up service is operational six days a week and customers will not have to endure long queues. They can collect their cash quickly and safely.
Andy Jury, CEO, Mukuru says of the expanded partnership, “This is yet another step in growing our vision of providing our customers with financial services that are easily accessible and convenient. Through this partnership, we have an opportunity to make remittance payments accessible to WorldRemit customers in remote areas through our extended booth network. We also guarantee cash availability at our booths with zero charges to the recipient when they collect their cash, so the recipient receives the full remittance sent to them.”
Pardon Mujakachi, Head of Sub Saharan Africa at WorldRemit commented “The response to our service launch in Zimbabwe was phenomenal, and we are happy to be able to offer our customers in Zambia, South Africa, Mozambique, Malawi and Botswana the same unmatched customer experience providing low cost and convenient access to remittances, no matter the location. As we expand on our partnership, our joint efforts for financial inclusion is creating a positive shift for our customers on the African continent. The WorldRemit service is 100% digital on the send side via the WorldRemit website or mobile app, providing 24/7 access to remittances from 50+ send countries, into over 7,000 Mukuru cash pick-up locations across the five countries we are newly launching.”
ENDS
About WorldRemit
WorldRemit is a leading global payments company. We disrupted an industry previously dominated by offline legacy players by taking international money transfers online - making them safer, faster and lower-cost. We currently send from 50 to 150 countries, operate in 6,500 money transfer corridors worldwide and employ over 1,100 people globally.
On the sending side WorldRemit is 100% digital (cashless), increasing convenience and enhancing security. For those receiving money, the company offers a wide range of options including bank deposit, cash collection, mobile airtime top-up and mobile money.
Backed by Accel, TCV and Leapfrog – WorldRemit’s headquarters are in London, United Kingdom with regional offices in the United States, Canada, Australia, New Zealand, Hong Kong, Singapore, Malaysia, South Africa, Somaliland, Rwanda, Zimbabwe and Belgium.
For more information, visit www.worldremit.com
About Mukuru
Mukuru is an Africa-based FinTech that enables safe, affordable, reliable financial services to underserved communities. With over 30 million cross-border transactions over the last decade, we are one of Africa’s largest remittances-led FinTech’s. Our remittance service offers customers the opportunity to send money to their relatives or friends in over 20 countries across Africa and Asia.
Additionally, we offer critical customer services such as Funeral Cover, The Mukuru Money Card and payment solutions for businesses in emerging markets.
For more information, visit https://www.mukuru.com/sa/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005364/en/
Contact information
For media inquiries:
WorldRemit
Genevieve Dowokpor: gdowokpor@worldremit.com
Mukuru
Cindy Klassen: cindy@mukuru.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom